Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Propositions
Value Propositions
Value Propositions
,
Value Peer-spectives
September 2010, Vol 1, No 4
dding trastuzumab to standard cisplatinum/fluoropyrimidine chemotherapy for patients with HER2-positive advanced gastric cancer results in a median survival of 13.8 months, compared with 11.1 months with chemotherapy alone, according to a new study (
Lancet
. 2010;376 [9742]:687-97. Epub 2010 Aug 19).
Read Article
Value Propositions - October 2016
Value Propositions
,
Value Peer-spectives
October 2016, Vol 7, No 9
Read Article
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
By
Wayne Kuznar
Value Propositions
,
Value Peer-spectives
October 2015, Vol 6, No 9
Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.
Read Article
Value Propositions in Oncology: The Physician Perspective
By
Chase Doyle
Value in Oncology
,
Value Propositions
,
Value Peer-spectives
July 2015, Vol 6, No 6
Chicago, IL—The rising costs of cancer drugs and medical services, along with increased copays and high deductibles for patients, are adding a serious financial hardship to patients diagnosed with cancer, according to Neal J. Meropol, MD, Associate Director, Clinical Programs, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.
Read Article
Value Propositions - June 2015
Value Propositions
,
Value Peer-spectives
June 2015, Vol 6, No 5
Read Article
Value Propositions - May 2015
Economics & Value
,
Value Propositions
,
Value Peer-spectives
May 2015, Vol 6, No 4
Read Article
Value Propositions - April 2015
Value Propositions
,
Value Peer-spectives
April 2015, Vol 6, No 3
Read Article
Value Propositions - March 2015
Value Propositions
,
Value Peer-spectives
March 2015, Vol 6, No 2
Read Article
Value Propositions - October 2014
Value Propositions
,
Value Peer-spectives
October 2014, Vol 5 , No 8
Medicare now provides coverage for the only FDA-approved noninvasive stool DNA screening test for colorectal cancer (CRC), after the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination in October.
Read Article
Value Propositions - September 2014
Economics & Value
,
Value Propositions
,
Value Peer-spectives
September 2014, Vol 5, No 7
Read Article
Page 1 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma